News

In the dynamic world of today, role of combination products happens to be emerging as catalysts when it comes to transformative healthcare solutions. Defined widely as therapeutics or even diagnostic products integrating drugs and medical devices as well as...

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally come to a realization as the German drugmaker has purchased the Connecticut biopharma for an equity valuation of $3.9 billion, the company recently said. The deal, which amounts to $47 per...

Roche is planning to expand its drug production in the US and has announced a pledge to spend $50 billion in the next five years on new as well as existing manufacturing facilities across several states. This investment promise is...

Language barriers create significant challenges for non-native English speakers in healthcare settings. In the United States, English is the primary language, which complicates communication for non-English-speaking patients.  These patients often struggle to describe symptoms, understand instructions, and navigate the healthcare...

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics, has announced U.S. FDA approval of AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. This approval makes AMVUTTRA the first and...

Genmab has reported encouraging findings from the Phase 2 RAINFOL-01 trial of rinatabart sesutecan (Rina-S®), an experimental folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug combination (ADC). Data from the B1 cohort of the trial showed encouraging antitumor efficacy in highly pre-treated...

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong Pharma Support European life sciences investment firm Sofinnova Partners has announced the final close of its second biotech acceleration fund, raising €165 million and surpassing its original target. The fund, Sofinnova...